All patients who had received intravitreal anti-VEGF injections with ranibizumab (Lucentis; Novartis AG, Basel, Switzerland) and conbercept (Lumitin; Kanghong Biotech, Chengdu, PR China) between September 2012 and December 2017 were enrolled. The injections were performed at the Beijing Tongren Eye Center, Beijing, China. Presumed EO was defined as any intraocular inflammation treated with tap and inject, with or without vitrectomy. Aqueous humor and vitreous samples were cultured. All presumed EO cases were included regardless of the subsequent culture results, positive or negative. EO cases were excluded from our study if the intravitreal injection had been combined with another ocular procedure (i.e., cataract operation, vitrectomy, laser, and paracentesis). Informed consent was obtained from all patients before the injections. Our study was conducted in accordance with the tenets of the Declaration of Helsinki and approved by the Ethics Committee of the Beijing Tongren Hospital, Capital Medical University. The minimum follow-up duration for all cases in this study was one year.
Lucentis
Manufactured by Novartis
Sourced in Switzerland, United States, Germany
Lucentis is a prescription medication used to treat certain types of eye conditions. It is a biologic therapy that targets and inhibits a specific protein involved in the growth of abnormal blood vessels in the eye.
Automatically generated - may contain errors
Lab products found in correlation
Eylea, by Bayer (6 mentions)
Avastin, by Roche (4 mentions)
Avastin, by Genentech (2 mentions)
Visudyne, by Novartis (1 mentions)
Luminex 200, by Bio-Rad (1 mentions)
Ranibizumab, by Novartis (1 mentions)
Ozurdex, by Abbvie (1 mentions)
Alcaine eye drop, by Alcon (1 mentions)
Ki8751, by Selleck Chemicals (1 mentions)
Fluorescein dextran fitc, by Merck Group (1 mentions)
Axiophot, by Zeiss (1 mentions)
Spectramax i3x, by Molecular Devices (1 mentions)
Rabbit anti vegf, by Abcam (1 mentions)
Microscopy, by Zeiss (1 mentions)
Conjuncain, by Bausch & Lomb (1 mentions)
Ump3 2 ultra micro pump, by World Precision Instruments (1 mentions)
29 protocols using lucentis
1
Endophthalmitis Risk After Anti-VEGF Injections
2
Anti-VEGF Therapy for Macular Edema in CRVO
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
3
Aqueous Humor Sampling in nAMD and Cataract
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients with nAMD received the intravitreal anti-VEGF drugs injection. Limbal puncture was performed before vitreous injection. An equivalent of 50–100 μl AH was collected through the limbus with an insulin syringe. Subsequently, 0.05 ml of Lucentis (Novartis Pharma Schweiz, AG) was injected into the vitreous cavity to restore the intraocular pressure balance. 17 AH samples of the cataract group were collected from 17 patients with senile cataracts. At the beginning of phacoemulsification, the surgeon used insulin syringes to obtain 50–100 μl of undiluted AH samples through the corneoscleral margin incision that was then transported to the laboratory for analysis.
4
Intravitreal Ranibizumab for ICNV
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study was performed at the Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine. The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine, and the procedures used conformed to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients before study inclusion. Thirty-nine consecutive ICNV patients who were scheduled to undergo intravitreal injection of 0.5 mg ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) were studied.
Inclusion criteria for ICNV in this study were: (1) patients younger than 50 years; (2) previous untreated CNV; (3) OCT showing intraretinal edema, subretinal fluid (SRF), or pigment epithelial detachment (PED); and (4) absence of concurrent ocular diseases in the study eyes that compromised or could have compromised vision and ocular condition. Exclusion criteria were: (1) clinical features suggesting that CNV was secondary to other causes such as AMD, PM, trauma, or hereditary diseases; (2) axial length >26.0 mm or myopia> −6 diopter; (3) history of prior treatment for ICNV, including intravitreal drug injection, PDT, systemic or focal steroids; (4) previous intraocular surgery.
Inclusion criteria for ICNV in this study were: (1) patients younger than 50 years; (2) previous untreated CNV; (3) OCT showing intraretinal edema, subretinal fluid (SRF), or pigment epithelial detachment (PED); and (4) absence of concurrent ocular diseases in the study eyes that compromised or could have compromised vision and ocular condition. Exclusion criteria were: (1) clinical features suggesting that CNV was secondary to other causes such as AMD, PM, trauma, or hereditary diseases; (2) axial length >26.0 mm or myopia> −6 diopter; (3) history of prior treatment for ICNV, including intravitreal drug injection, PDT, systemic or focal steroids; (4) previous intraocular surgery.
5
Intravitreal Implant and Injection Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The study eye was anesthetized with topical and subconjunctival anesthetics and prepared according to standard clinical practice for intravitreal injection. In Group 1, a 0.7-mg dexamethasone implant was inserted into the vitreous cavity through the pars plana using a customized, single-use, 22-G applicator. In Group 2, 0.5 mg ranizumab/0.5 mg/mL (Lucentis; Novartis International AG, Basel, Switzerland) was inserted into the vitreous cavity through the pars plana using a customized, single-use, 30-G needle. Patients were treated with topical 0.5% moxifloxacin 4x daily starting 3 days before the day of the procedure, and for 3 days after the procedure.
6
Ranibizumab and Verteporfin for RAP
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients were treated with IV ranibizumab (Lucentis ® ; Novartis International AG, Basel, Switzerland), 0.5 mg/0.05 ml, in a nonloading dose pro re nata (PRN) regimen, with (n = 33) or without (n = 46) associated PDT with verteporfin (Visudyne ® ; Novartis International AG). Decision on retreatment was based on a decrease in BCVA ≥ 1 ETDRS line and/or OCT findings, specifically the presence of retinal pigment epithelium detachment, hemorrhage, and intra-or subretinal fluid. Each IV injection was performed 3.5-4.0 mm posterior to the corneal limbus using a 30-gauge needle after instillation of topical anesthesia and 5% povidone-iodine solution in the fornix. Prophylaxis of endophthalmitis was achieved with topical quinolone q.i.d. 4 days before and 4 days after the IV injection. PDT was performed only in cases included until December 2009, and discontinued after an intermediate analysis showed no additional benefit versus PRN IV ranibizumab monotherapy. When treating bilateral RAP, IV ranibizumab or PDT were performed on separate days.
7
Anti-VEGF Injections for Ocular Conditions
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The treatment protocol consisted of anti-VEGF intravitreal injections with either bevacizumab 1.25 mg/0.05 mL (Avastin; Roche, Basel, Switzerland) (46 patients) or ranibizumab 0.5 mg/0.05 mL (Lucentis; Novartis, Basel, Switzerland) (6 patients) administered at 2-month intervals during 12 months and at 3-month intervals during the second year. Intravitreal injections were performed at our institution or by the referring ophthalmologist. However, the clinical evaluations were carried out at our institution at 6-month intervals. The use of intravitreal VEGF inhibitors is off-label in this condition.
8
Aqueous Humor Cytokine Profile in nAMD
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients initially diagnosed with nAMD or PCV who were in the acute phase received the anti-VEGF drugs ranibizumab (0.5 mg/0.05 ml, Lucentis; Novartis Pharma AG, Basel, Switzerland) or conbercept (0.5 mg/0.05 ml, KH902; Biotech Co., Ltd., Sichuan, China) therapy. Retreatment or change of treatment regimen was considered according to clinical response at a 1-month follow-up. AH samples were collected before cataract surgery in the control group or before intravitreal anti-VEGF drugs (ranibizumab or conbercept) injection into the eyes with nAMD or PCV. After topical anesthesia, ~0.05–0.1 ml of AH was withdrawn at the corneal limbus using a tuberculin syringe with a 30-gauge needle. The samples were immediately frozen and stored at −80°C until analysis of the cytokines. Luminex200 (BIO-RAD, Hercules, CA, USA) was used for the detection of VEGF, interleukin 6 (IL-6), IL-8, IL-10, interferon-inducible protein 10 (IP-10), and monocyte chemotactic protein 1 (MCP-1). The concentration of AH cytokine was calculated and presented as pg/ml from the standard curve of each specific cytokine provided by the kit (LXSAHM-06, RnD).
9
Intravitreal OPT-302 and Ranibizumab for Neovascular AMD
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The 0.5 mg OPT-302 group received intravitreal 0.5 mg OPT-302 (50 μl) plus intravitreal 0.5 mg ranibizumab (50 μL; Lucentis, Novartis, Genentech); the 2.0 mg OPT-302 group received intravitreal 2.0 mg OPT-302 (50 μl) plus intravitreal 0.5 mg ranibizumab (50 μl); and the sham group received a sham intravitreal injection plus intravitreal 0.5 mg ranibizumab (50 μl). The ranibizumab injection was delivered before the OPT-302/sham injection. The sham injection was delivered by pressing the syringe hub against the conjunctiva (further details are described in the Supplementary Protocol and Statistical Analysis Plan, available at www.aaojournal.org). Key ocular assessments included ETDRS BCVA, ocular examination, IOP, and spectral-domain OCT (SD-OCT), repeated 4-weekly. The National Eye Institute 25-item Visual Function Questionnaire (VFQ-25) was completed at baseline and week 24, with fluorescein angiography and color photography at baseline, week 12, and week 24 (Table S1, available at www.aaojournal.org).
10
Intravitreal Anti-VEGF Injections for Radiation Maculopathy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients diagnosed with radiation maculopathy were advised to follow a strict treatment protocol by intravitreal anti-VEGF injections. It consisted of intravitreal anti-VEGF injections by either bevacizumab 1.25 mg/0.05 mL (Avastin; Roche, Basel, Switzerland) or ranibizumab 0.5 mg/0.05 mL (Lucentis; Novartis, Basel, Switzerland) administered at 2-month intervals during 6 months (3 injections). Intravitreal injections were performed at our institution or by the referring ophthalmologist, and the final clinical evaluation was carried out at Month 6 at our institution.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!